IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sha

IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Inactivated polio vaccine (IPV) is also known as Salk vaccine. For the vaccination against polio there are two vaccines available: inactivated polio vaccine and oral polio vaccine. The IPV vaccine is mostly given in arm or leg as a shot.
Individuals who are allergic to eggs or the drugs such as streptomycin should not receive the injectable IPV. The IPV is only given if the vaccine recipient is on steroid therapy for long-term, has cancer, or is on ongoing process of chemotherapy or there is any unimmunized adult in house.
Global IPV vaccines market was valued at US$ 160 Mn in 2021 and is expected to increase to US$ 240 Mn by 2028, registering a CAGR of 8.5% over the forecast period.
Market Dynamics
Various governments have taken initiatives to increase awareness regarding vaccination to prevent occurrence of polio among the population. Public introduced beneficial immunization programs to provide vaccination to poor people, which is expected to create a highly conducive environment for growth of the Global Inactivated Polio Vaccines Market (IPV) in the near future. For instance, in September 2019, the Ghana Health Service (GHS), launched series of polio vaccination/immunization campaign to prevent spreading of the virus in high risk areas. The immunization polio vaccination campaign will use the inactivated polio vaccine (IPV) to immunize all the children born from January 2016 to June 2018 in all districts across Ghana.
Key features of the study:
This report provides in-depth analysis of the Global IPV vaccines market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global IPV vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The IPV vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global IPV vaccines market
Detailed Segmentation:
Global IPV Vaccines Market, by Vaccine Brand:
Poliovac (Pfs/Sd)
Shanipv
Poliorix
Ipol/Imovax
Polymilex
Global IPV Vaccines Market, by Distribution Channel:
Private
Public
Global IPV Vaccines Market, by Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles:
GlaxoSmithKline Plc*
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
PT Bio Farma
AJ Vaccines
“*” marked represents similar segmentation in other categories in the respective section.